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Aims To determine whether plasma apoE levels and APOE genotype are associated with all-cause and cause-specific
mortality.
...................................................................................................................................................................................................
Methods
and results
Using a prospective cohort design with 105 949 white individuals from the general population, we tested the asso-
ciation between plasma apoE at study enrolment and death during follow-up, and whether this was independent of
APOE genotype. We confirmed the well-known association between APOE genotypes and mortality. For all-cause,
cardiovascular, and cancer mortality, high levels of apoE were associated with increased risk, while for dementia-
associated mortality low levels were associated with increased risk. For the highest vs. the fifth septile of plasma
apoE, hazard ratios (HRs) were 1.20 (95% confidence interval 1.12–1.28) for all-cause mortality, 1.28 (1.13–1.44)
for cardiovascular mortality, and 1.18 (1.05–1.32) for cancer mortality. Conversely, for the lowest vs. the fifth sep-
tile the HR was 1.44 (1.01–2.05) for dementia-associated mortality. Results were similar in analyses restricted to
APOE e33 carriers. Examining genetically determined plasma apoE, a 1 mg/dL increase conferred risk ratios of 0.97
(0.92–1.03) for cardiovascular mortality and 1.01 (0.95–1.06) for cancer mortality, while a 1 mg/dL decrease con-
ferred a risk ratio of 1.70 (1.36–2.12) for dementia-associated mortality.
...................................................................................................................................................................................................
Conclusion High plasma levels of apoE were associated with increased all-cause, cardiovascular, and cancer mortality, however
of a non-causal nature, while low levels were causally associated with increased dementia-associated mortality.
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Introduction
The basis of human longevity and healthy ageing remains among the
principal questions in biology and medicine. Life expectancy is chal-
lenged by major diseases in old age—among these, dementia and car-
diovascular disease. Alzheimer disease, the most common form of
dementia, is a major cause of disability in later life with an increasing
global prevalence, and this presently untreatable disease deteriorates
into an inevitable terminal stage.1–5 Cardiovascular disease is the
leading cause of death worldwide,6 and only in Central and Western
Europe has the annual number of deaths from cardiovascular disease
declined.7,8 Biomarkers of lipid metabolism have been associated
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with increased mortality, however, the relationship of plasma levels
of a crucial lipid transport protein, apolipoprotein E (apoE), with
mortality is presently unknown.
ApoE plays a pivotal role in both peripheral and cerebral choles-
terol metabolism. In plasma, apoE is mainly carried by triglyceride-
rich lipoproteins, and serves as a ligand for members of the low-
density lipoprotein (LDL) receptor family.9 In the brain, astrocyte-
derived apoE is crucial for cerebral cholesterol metabolism and clear-
ance of b-amyloid, an important pathological hallmark of Alzheimer
disease.10,11 Plasma levels of apoE and other lipids and lipoproteins
are under strong genetic influence by the well-known APOE poly-
morphism—a combination of two genetic variants (rs429358 and
rs7412) giving rise to six common APOE genotypes, e22, e32, e33,
e42, e43, and e44. Both e2 and e4 alleles are associated with un-
favourable lipid profiles,12–19 and the e4 allele is a strong genetic risk
factor for Alzheimer disease,20 and by far the strongest hit in
genome-wide association studies of longevity.21,22 Interestingly, low
levels of plasma apoE were recently reported to be associated with
increased risk of dementia,17,23,24 whereas high levels were associ-
ated with increased risk of ischaemic heart disease.25 Hence both a
quantitative importance of plasma apoE levels, and a qualitative gen-
etically determined effect, appears to be important for dementia and
cardiovascular disease—two important determinants of life expect-
ancy. A few studies have addressed the association between plasma
apoE and cardiovascular mortality.26,27 Beyond that, the relationship
of plasma apoE levels with all-cause and cause-specific mortality is un-
known. Such associations are of substantial interest, because they
may generate therapeutic and clinical considerations.
We studied the association of plasma apoE levels with all-cause
and cause-specific mortality and assessed whether this was independ-
ent of isoform differences due to APOE genotype, by evaluating both
APOE genotype adjusted and e33 genotype stratified analyses. Using a
Mendelian randomization design, we also studied genetically deter-
mined plasma apoE levels to examine if plasma apoE was causally
associated with cause-specific mortality. For this purpose, we studied
two large prospective cohorts of the white Danish general popula-
tion, the Copenhagen General Population Study (CGPS) and the
Copenhagen City Heart Study (CCHS), totalling 105 949 individuals.
Methods
Studies were approved by institutional review boards and Danish ethical
committees and were conducted according to the Declaration of
Helsinki, with written informed consent from participants. All individuals
were white and of Danish descent. There was no overlap of individuals
between studies.
Participants
We included individuals from two similar studies of the Danish general
population: The Copenhagen General Population Study (CGPS) and the
Copenhagen City Heart Study (CCHS). Individuals were randomly
selected from the national Danish Civil Registration System to reflect the
adult white population aged 20 to 100þ years. The studies combined
included a total of 105 949 individuals, of whom 13 693 died during the
follow-up period.
The Copenhagen General Population Study
This prospective study of the Danish general population was initiated in
2003 with the first enrolment period from 2003 to 2015 and with follow-
up examinations ongoing.17,24,28,29 Data collection included a question-
naire, a physical examination, and blood sampling for biochemical and
DNA analyses. We included 95 583 individuals; among these, 8321 died
during follow-up.
The Copenhagen City Heart Study
This prospective study of the Danish general population was initiated in
1976–78 with follow-up examinations in 1981–83, 1991–94, and 2001–
03.17,24,28,29 Participants were recruited and examined as in the CGPS.
We included 10 366 individuals who gave blood for biochemical and
DNA analyses at the 1991–94 or 2001–03 examinations; among these,
5372 died during follow-up.
Endpoints
Endpoints are described in detail in the Supplementary material online.
Follow-up began at the time of blood sampling (2003–13 and onwards
for CGPS and 1991–94 or 2001–03 and onwards for CCHS). For all-
cause mortality, follow-up ended at occurrence of death, emigration, or
on 22 March 2017 (last update of the registries), whichever came first.
Median follow-up was 8.5 years (range 0–25 years) for all-cause mortality,
with no individuals lost to follow-up. End of follow-up for the national
Danish Causes of Death Registry (31 December 2015) lags the Danish
Civil Registration System (22 March 2017) by more than 1 year: as a con-
sequence some deaths could not be classified by cause (1839 of 13 693
deaths), and cause-specific mortality follow-up was truncated accordingly
on 31 December 2015.
Biochemical and genetic analyses
Apolipoprotein E was measured using nephelometry or turbidimetry
(Dade Behring, Deerfield, Illinois, USA, or Dako, Glostrup, Denmark) as
previously described.17,25 An ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems Inc., Foster City, CA, USA) and Taqman
based assays were used to genotype for p.Cys130Arg (rs429358, legacy
name Cys112Arg, c.388T>C) defining the e4 allele and p.Arg176Cys
(rs7412, legacy name Arg158Cys, c.526C>T) defining the e2 allele. A
total of 105 949 individuals (with 13 693 deaths) were genotyped, and for
104 153 of these individuals (with 13 312 deaths) plasma apoE measure-
ments were obtained. Genotypes for three APOE promotor variants
(rs449647, rs769446, and rs405509) in 74 560 individuals were deter-
mined similarly, as previously reported.24
Other covariates
Body mass index was measured weight in kilograms divided by measured
height in metres squared. All other covariates were self-reported and
described in detail in the legend to Table 1.
Statistical analysis
We used Stata/S.E. version 13.1 (Stata Corp., College Station, TX, USA).
P-values were two-sided and values <0.0001 are given as powers of 10.
Statistical analyses are described in detail in the Supplementary material
online.
Results
During up to 25 years of follow-up, 13 693 individuals in the CGPS
and CCHS died. Baseline characteristics of individuals with low
2814 K.L. Rasmussen et al.
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..(<_4.5 mg/dL) and high (>4.5 mg/dL) plasma apoE are shown in
Table 1, and sex stratified results are shown in Table 2. The overall
mean value of plasma apoE for the population was 4.3 mg/dL
(Supplementary material online, Figure S1). We found no interaction
between seven groups of plasma apoE and study (P for inter-
action = 0.26). Consequently, all further analyses were performed on
the studies combined.
APOE genotype and all-cause and cause-
specific mortality
The Kaplan–Meier survival curves for overall survival for the six com-
mon APOE genotypes showed an increased mortality risk for individu-
als carrying the e44 genotype relative to e33 individuals
(Supplementary material online, Figure S2), and with similar patterns
in women and men separately (Supplementary material online, Figure
S3). Median survival decreased from 86.9 years in e32 carriers to 86.4
in e33 carriers to 86.3 in e22 carriers to 86.1 in e42 carriers to 85.9 in
e43 carriers through to 83.7 years in e44 carriers. All-cause, cardio-
vascular, and dementia-associated mortality increased correspond-
ingly from e32 to e33/e22 to e42/e43 to e44 (Figure 1). Hazard ratios
(HRs) for all-cause mortality were 1.10 (1.06–1.14) for e43 carriers
and 1.43 (1.29–1.58) for e44 carriers vs. e33 carriers (Figure 1), with
similar patterns in women and men separately (Supplementary ma-
terial online, Figure S4). For the six APOE genotypes, total cholesterol,
LDL cholesterol, and apolipoprotein B increased from e22 to e32 to
e42 to e33 to e43 to e44 (P for trends < 1 10-300), whereas plasma
apoE, high-density lipoprotein (HDL) cholesterol, and apolipoprotein
AI levels decreased from e22 to e32 to e42 to e33 to e43 to e44 (P
for trends <_ 2 10-76) (Figure 2). For triglycerides and remnant chol-
esterol U-shaped curves were observed with the highest levels in e22
and e44 carriers (P= 1 10-65 and 7 10-62), whereas the highest
lipoprotein(a) level was observed in e33 carriers (P= 2 10-40)
(Figure 2).
Plasma levels of apolipoprotein E and all-
cause and cause-specific mortality
Multifactorially adjusted (including LDL cholesterol, HDL cholesterol,
and triglycerides) restricted cubic spline Cox regression models eval-
uated risk of all-cause mortality by plasma apoE levels, further
adjusted for APOE genotype (Figure 3, upper panel) or in e33 carriers
only (Figure 3, bottom panel). All-cause mortality increased with
increasing levels of apoE relative to the reference of 4.5 mg/dL. There
..............................................................................................................................
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of individuals in the general population with low and high plasma apolipoprotein E
Characteristic Plasma apolipoprotein E
4.5 mg/dL >4.5 mg/dL P-valuea
Individuals, N 67 023 37 130 —
Women (%) 52 60 5 10-128
Age (years) 56.4 ± 0.1 60.0 ± 0.1 <1 10-300
Body mass index (kg/m2) 25.7 ± 0.0 26.9 ± 0.0 <1 10-300
Hypertension (%) 56 66 6 10-254
Diabetes mellitus (%) 4 4 0.01
Smoking (%) 21 21 0.65
High alcohol consumption (%) 16 19 8 10-28
Physical inactivity (%) 48 54 1 10-69
Postmenopausal (%)c 59 80 <1 10-300
Hormonal replacement therapy (%)b 11 10 0.01
Lipid-lowering therapy (%) 12 8 6 10-119
Education<8 years (%) 11 15 5 10-61
APOE genotype (%) <1 10-300
e22 0 2
e32 4 28
e33 58 51
e42 1 6
e43 32 13
e44 4 1
Values are presented as number, mean ± standard error of the mean, or percentage and are from the day of enrolment (2003–13 for the Copenhagen General Population
Study and 1991–94 or 2001–03 for the Copenhagen City Heart Study). Missing data on categorical and continuous covariates (<0.3%) were imputed from age, sex, and popula-
tion. Hypertension was defined as use of antihypertensive medication, systolic blood pressure of >_140 mmHg, and/or diastolic blood pressure of >_90 mmHg. Diabetes mellitus
was defined as self-reported disease, use of insulin or oral hypoglycaemic agents, and/or non-fasting plasma glucose level of >11 mmol/L (>198 mg/dL). Smoking was defined as
current smoking. High alcohol consumption was defined as >14/21 U per week for women/men [1 U = 12 g alcohol, equivalent to 1 glass of wine or spirit or 1 beer (33 cl)].
Physical inactivity was defined as <_4 h per week of light physical activity in leisure time. Women reported menopausal status and use of hormonal replacement therapy. Lipid-
lowering therapy was primarily statins (yes/no), and the cut-off for low education was 8 years.
aP for differences by the Kruskal–Wallis equality-of-populations rank test or by the Pearson’s v2 test, as appropriate.
bIn women only.
Apolipoprotein E and mortality 2815
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.was no sign of non-linearity for all-cause and cause-specific mortality
(P>_ 0.30). We found interaction between seven groups of plasma
apoE and sex on all-cause and cardiovascular mortality (P for inter-
action = 0.02 and 0.006), but no interaction for seven groups of
plasma apoE and sex on dementia-associated and cancer mortality (P
for interaction = 0.10 and 0.12). The associations between high levels
of apoE and all-cause, cardiovascular, and cancer mortality appeared
augmented in men (Supplementary material online, Figures S5–S7);
otherwise largely similar patterns were observed in women and men,
although overall with attenuation in women compared with in men.
High plasma levels of apoE were associated with increased risk of
cardiovascular and cancer mortality in the APOE adjusted model and
in e33 carriers only (Figure 4, left and right panels). Conversely, low
plasma levels of apoE were associated with increased dementia-
associated mortality, in the APOE adjusted model and in e33 carriers
only (Figure 4, middle panel).
For the highest vs. the fifth septile of apoE, HRs were 1.20 (95%
confidence interval 1.12–1.28) for all-cause mortality, 1.28 (1.13–
1.44) for cardiovascular mortality, and 1.18 (1.05–1.32) for cancer
mortality (Figure 5). Conversely, for the lowest vs. the fifth septile the
HR was 1.44 (1.01–2.05) for dementia-associated mortality (Figure 5).
Analyses solely in e33 carriers showed similar patterns (Figure 5,
lower panels).
Causal estimates
Estimates from instrumental variable analyses for plasma apoE per se
indicated causality for dementia-associated mortality but not for car-
diovascular and cancer mortality (Figure 6); because of the observed
opposite association observationally between plasma apoE and re-
spectively cardiovascular and dementia-associated mortality, we did
not perform instrumental variable analysis for all-cause mortality.
Examining genetically determined plasma apoE, a 1 mg/dL increase
conferred risk ratios of 0.97 (0.92–1.03) for cardiovascular mortality
and 1.01 (0.95–1.06) for cancer mortality, while a 1 mg/dL decrease
conferred a risk ratio of 1.70 (1.36–2.12) for dementia-associated
mortality for univariable analyses (Figure 6). Plasma levels of apoE and
HDL cholesterol decreased, while LDL cholesterol increased across
apoE decreasing weighted and simple allele score groups
(Supplementary material online, Figure S8).
Sensitivity analyses
As apoE plays a central part in lipoprotein metabolism and plasma
level and isoform specific differences of apoE are associated with lev-
els of lipids and lipoproteins in peripheral lipid metabolism (Figure 2),
we also evaluated a multifactorially adjusted model without adjust-
ment for LDL cholesterol, HDL cholesterol, and triglycerides.
..........................................................................................................................................................
...................................................................... ...........................................................................
....................................................................................................................................................................................................................
Table 2 Baseline characteristics for women and men in the general population with low and high plasma apolipopro-
tein E
Characteristic Plasma apolipoprotein E
Women Men
4.5 mg/dL >4.5 mg/dL P-valuea 4.5 mg/dL >4.5 mg/dL P-valuea
Individuals, N 35 087 22 314 —b 31 936 14 816 5 10-128 b
Age (years) 55.0 ± 0.1 61.2 ± 0.1 <1 10-300 57.9 ± 0.1 58.3 ± 0.1 0.13
Body mass index (kg/m2) 25.0 ± 0.0 26.4 ± 0.0 8 10-282 26.4 ± 0.0 27.6 ± 0.0 3 10-240
Hypertension (%) 48 63 5 10-270 64 72 3 10-60
Diabetes mellitus (%) 3 3 0.01 5 5 1 10-4
Smoking (%) 20 19 0.02 21 23 0.003
High alcohol consumption (%) 13 16 2 10-13 19 24 9 10-29
Physical inactivity (%) 53 57 3 10-22 43 50 2 10-36
Postmenopausal (%)c 59 80 <1 10-300 — — —
Hormonal replacement therapy (%)c 11 10 0.01 — — —
Lipid-lowering therapy (%) 10 8 6 10-20 15 8 4 10-106
Education<8 years (%) 10 15 9 10-88 13 14 0.001
APOE genotype (%) <1 10-300 <1 10-300
e22 0 2 0 2
e32 4 26 4 30
e33 57 53 60 47
e42 1 6 1 6
e43 34 13 31 14
e44 5 1 3 1
Values are presented as number, mean ± standard error of the mean, or percentage and are from the day of enrolment (2003–13 for the Copenhagen General Population
Study and 1991–94 or 2001–03 for the Copenhagen City Heart Study). Missing data and definitions of variables were identical to the descriptions given in the legend to Table 1.
aP for differences by the Kruskal–Wallis equality-of-populations rank test or by the Pearson’s v2 test, as appropriate.
bOne test for men and women with low and high apoE.
cIn women only.
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..In these analyses, risk of all-cause mortality increased with both
increasing and decreasing levels of apoE relative to the reference
value of 4.5 mg/dL, which defined the overall lowest all-cause mortal-
ity (Supplementary material online, Figures S9 and S10; compare with
Figures 3 and 5). We found results similar to those in Figure 5, when
excluding individuals contributing with more than one cause-specific
event (Supplementary material online, Figure S11), or when using ter-
tiles, quartiles, quintiles, or deciles instead of septiles (Supplementary
material online, Figure S12). We found no interaction between seven
groups of plasma apoE and use of two different autoanalyzers on all-
cause mortality (P for interaction = 0.80) and estimates before and
after the change were similar (Supplementary material online, Figure
S13). Sensitivity analyses for risk of narrower cardiovascular mortality
endpoints showed similar patterns as for all cardiovascular mortality
(compare Supplementary material online, Figure S14 with Figure 1).
Results for cause-specific mortality adjusted for multiple hypothesis
testing are shown in Supplementary material online, Figure S15.
Instrumental variable sensitivity analyses showed no major deviations
and did not change conclusions from the main findings in Figure 6
(compare with Supplementary material online, Table S1 and Figure
S16).
Discussion
In this study of 105 949 individuals from the white general population,
high plasma levels of apoE were associated with high all-cause mortal-
ity. For cause-specific mortality, high apoE levels were associated
Figure 1 Risk of all-cause, cardiovascular, dementia-associated, and cancer mortality as a function of APOE genotype. Cox regression models were
adjusted for age (time scale), body mass index, smoking, hypertension, diabetes, lipid-lowering therapy, alcohol consumption, physical inactivity, edu-
cation, postmenopausal status, hormonal replacement therapy, LDL cholesterol, HDL cholesterol, and plasma triglycerides. APOE, APOE e2/e3/e4
genotype; CI, confidence interval.
Apolipoprotein E and mortality 2817
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..with high cardiovascular mortality, however of a non-causal nature,
while low apoE levels were causally associated with high dementia-
associated mortality (Take home figure). These findings are novel.
That both extreme high and low plasma levels of apoE is associated
with cause-specific mortality is biologically plausible and is most likely
explained by the fact that low apoE levels are associated with risk of
dementia17,23,24 and thus reflected in dementia-associated mortality,
whereas high apoE levels are associated with atherogenic lipids and
lipoproteins and with risk of ischaemic heart disease25,30,31 and car-
diovascular mortality.26,27 A previous meta-analysis comprising
9500 individuals found an association for fatal coronary heart dis-
ease after adjustment for LDL cholesterol, but showed only tenden-
cies for fatal stroke and non-fatal coronary heart disease.27 In our
study, the association between high apoE levels and all-cause and car-
diovascular mortality remained after adjustment for lipids, lipopro-
teins, and APOE genotype, and in analyses restricted to e33 carriers
only, most likely reflecting a general correlation between apoE levels
and atherogenic triglyceride-rich lipoproteins, independent of APOE
genotype. Low apoE levels were associated with dementia-
associated mortality in APOE genotype adjusted analyses and in e33
carriers only, more pronounced in men than in women. Since low
apoE levels repeatedly have been associated with high risk of demen-
tia, independent of the strong per e4 APOE allele effect,17,23,24 a re-
flection in dementia-associated mortality makes sense biologically.
Since it is well-established that the APOE e4 allele is associated with
increased mortality,32–40 we included analyses of APOE genotype as a
positive control and were additionally able to show that the associ-
ation between apoE levels and cardiovascular mortality, dementia-
associated and cancer mortality was independent of the important e4
allele. Our findings of APOE genotype and cause-specific mortality are
in agreement with previous findings,33,35,36,40,41 identifying especially
e32 as associated with decreased and e43 and e44 as associated with
increased mortality. Further, e32 may be protective of dementia-
associated mortality, in accordance with the higher apoE levels asso-
ciated with lower dementia-associated mortality. However, apolipo-
protein E is a rather complicated lipid risk factor because quantitative
as well as qualitative genotype-determined isoform specific effects
each influence levels of lipids and lipoproteins; overall, high levels of
apoE are associated with high levels of triglycerides, which we have
shown previously.25 ApoE levels are however also influenced by their
genotype with the well-established patterns observed in Figure 2.
When assessed by genotype, those with the lowest apoE levels (e44)
are the ones with the highest risk for both cardiovascular and
dementia-associated mortality. This is most likely explained by the
fact that genotypes with low apoE in addition are associated with an
atherogenic lipid profile, and thus risk of cardiovascular disease and
cardiovascular mortality, whereas for dementia and dementia-
associated mortality, low apoE in plasma most likely mimic low apoE
levels in the brain resulting in decreased b-amyloid clearance.
Mechanisms underlying the association between high apoE levels
and increased all-cause and cardiovascular mortality are likely due to
the key function of apoE in receptor-mediated endocytosis by bind-
ing to triglyceride-rich lipoproteins, and serving as a ligand for the
LDL receptor and LDL receptor Related Protein (LRP).9 In mice,
overexpression of apoE has been shown to lead to hypertriglyceri-
daemia, and in vitro increase in apoE expression by hepatoma cells
correlates with increased very low-density lipoprotein synthesis and/
or secretion irrespective of apoE isoform.42 Hypertriglyceridaemic
patients have higher plasma levels of apoE compared with normal
control subjects, a finding probably explained by the mechanism that
increased levels of apoE stimulate very low-density lipoprotein trigly-
ceride production in the liver and impairs lipoprotein lipase-mediated
lipolysis, thus leading to hypertriglyceridaemia.42,43 Also, the well-
known propensity of LDL receptor affinity defective e22 carriers to
Figure 2 Plasma levels of lipids, lipoproteins, and apolipoproteins as a function of APOE genotype. Geometric mean ± standard errors of the mean
are given for apolipoprotein E, triglycerides, and lipoprotein(a); arithmetic mean ± standard errors of the mean are given for total cholesterol, LDL
cholesterol, apolipoprotein B, HDL cholesterol, apolipoprotein A1, and remnant cholesterol. APOE e2/e3/e4 genotypes are ordered according to
decreasing plasma apoE levels. Differences in plasma levels of lipids, lipoproteins, and apolipoproteins are given in percent (D%); e33 serves as the ref-
erence. P for trend (from e22 to e32 to e42 to e33 to e43 to e44) or the Kruskal–Wallis analysis of variance are given. APOE, APOE e2/e3/e4 genotype;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; Ref, reference.
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develop type III hyperlipoproteinaemia support this understanding.9
Only <1% of the general population are however e22 carriers and
will thus only account for a minor fraction of our overall findings of
high plasma apoE and high all-cause and cardiovascular mortality. As
triglyceride-rich lipoproteins are atherogenic and causally associated
with cardiovascular disease,44,45 and also associated with mortal-
ity,46,47 our findings of high apoE levels and high cardiovascular mor-
tality may be mediated by triglyceride-rich lipoproteins via remnant
cholesterol content, although our results did not change after adjust-
ment for triglycerides, LDL cholesterol, and HDL cholesterol. It is
Figure 3 Multifactorially adjusted hazard ratios for all-cause mortality according to plasma levels of apolipoprotein E in individuals in the general
population. Solid lines are multifactorially adjusted hazard ratios, whereas dashed lines indicate 95% confidence intervals derived from restricted cubic
splines with three knots and with the reference defined as the plasma level of apolipoprotein E with lowest overall mortality (4.5 mg/dL). Graphs are
truncated at the level of 2.1 mg/dL and 7.1 mg/dL, due to statistically unstable estimates at extreme low and high levels thus only including 98 350 indi-
viduals from the Copenhagen General Population Study and the Copenhagen City Heart Study in these analyses (56 264 in the e33 genotype strati-
fied analyses). Cox regression models were adjusted for age (time scale), sex, body mass index, smoking, hypertension, diabetes, lipid-lowering
therapy, alcohol consumption, physical inactivity, education, postmenopausal status, hormonal replacement therapy, LDL cholesterol, HDL choles-
terol, and plasma triglycerides (both panels), and further adjustment for APOE genotype in the upper panel while analyses were restricted to e33 car-
riers in bottom panels. 95% CI, 95% confidence interval; APOE, APOE e2/e3/e4 genotype; e33, APOE wildtype carriers.
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..puzzling that our results do not attenuate after these lipid adjust-
ments, and fuels speculations on a less lipid dependent effect of
plasma apoE on cardiovascular mortality, e.g. involvement in throm-
bosis and bleeding as suggested in a recent experimental study.48
These speculations are however purely theoretical and need further
experimental and clinical scrutinization. Further, mechanisms under-
lying the association between high apoE levels and increased cancer
mortality could likely be due to apoE involvement in metastasis and
angiogenesis.49–56 The present Mendelian randomization estimates
suggest however that the observational findings are not of a causal
nature.
Plausible mechanisms underlying the association between low
apoE levels and dementia-associated mortality are not explained by
peripheral lipid metabolism, but likely by the role of apoE in b-amyl-
oid handling and in neurodegenerative processes.57,58 The e4 allele
has detrimental effects on production, deposition, and clearance of
amyloid-b, in phosphorylation of tau, in neurotoxicity, mitochondrial
dysfunction, and in blood–brain barrier permeability.57,59,60 Also, re-
cently the effect of low apoE levels per se, independent of the e4 al-
lele, was observed to be associated with high risk of dementia in
three independent prospective European cohorts,17,23 and further
suggested to mark causal pathways in the brain.24 These robust find-
ings of low apoE on dementia risk most likely explain the observed
associations with dementia-associated mortality.
As outlined above, apoE is involved in different mechanisms in the
periphery and in the central nervous system. Human liver transplant-
ation studies clearly showed that apoE in the peripheral circulation
and in the central nervous system originates from two separate
compartments.61 Further, previous work suggest a limited blood–
brain barrier permeability to circulating lipid-poor apoE,62 suggesting
that apoE in blood and brain are regulated independently.61,63 Levels
of apoE in human cerebrospinal fluid display a similar genotype-
dependent pattern as in plasma,64 and in murine interstitial fluid a
similar genotype-dependent pattern as in cerebrospinal fluid was
observed.65 Hence, we suggest that plasma levels of apoE mirror lev-
els in cerebrospinal fluid and brain, despite originating from two dif-
ferent compartments.
We further substantiated our findings by causal genetic estimates
from instrumental variable analyses, which indicated a causal associ-
ation between plasma apoE levels and dementia-associated mortality
but not with cardiovascular or cancer mortality. We chose to use an
instrument consisting of five variants (three promoter variants and
two common exonic variants), because this combination of variants
reflects the quantitative effects of apoE as well as the qualitative, iso-
form specific effects. Because APOE variants not only affect plasma
levels of apoE but also all other major lipid, lipoprotein, and apolipo-
protein classes—a well-established biological fact due to the funda-
mental role of apoE in lipid metabolism—it is difficult to decipher
whether it is plasma levels of apoE per se that is responsible for a po-
tential causal association, or whether the other affected lipid, lipopro-
tein, or apolipoprotein traits are responsible. This phenomenon is
referred to as so-called vertical pleiotropy and may be overcome by
applying multivariable instrumental variable analysis, which we did to-
gether with a series of other relevant MR sensitivity analyses.66–68
These analyses showed no major deviations and did not change con-
clusions from the main instrumental variable findings. Mendelian
Figure 4 Multifactorially adjusted hazard ratios for cause-specific mortality according to plasma levels of apoE in individuals in the general popula-
tion. Solid lines are hazard ratios, whereas dashed lines indicate 95% confidence intervals derived from restricted cubic spline regression models simi-
lar to Figure 3 with respect to reference (4.5 mg/dL) and truncation (2.1–7.1 mg/dL). Cox regression models were multifactorially adjusted similar to
Figure 3, with additional adjustment for APOE genotype in upper panels and with analyses restricted to e33 carriers in bottom panels. 95% CI, 95%
confidence interval; APOE, APOE e2/e3/e4 genotype; e33, APOE wildtype carriers.
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randomization analyses for peripheral effects of apoE should how-
ever still be interpreted with caution when pleiotropy is a direct
cause of the biology of apoE. In contrast, it seems more straight for-
ward to use the instrument for dementia-associated mortality, be-
cause the brain relies almost exclusively on HDL-like apoE-
containing lipoprotein particles for its lipid transport and does not
have apoB and apoB-containing lipoproteins (LDL and triglyceride-
rich lipoproteins). Thus, the lipid and lipoprotein pleiotropic effects
in the periphery will most likely not be an issue in the brain. Despite
the current limitations, we obtained causal estimates that make bio-
logical sense: high plasma levels of apoE are not causally associated
with cardiovascular and cancer mortality, whereas low plasma levels
of apoE—mimicking brain apoE levels—are suggested to play a causal
role in dementia-associated mortality.
Results from the present study may generate therapeutic and clin-
ical considerations. Since both extreme high and low apoE were asso-
ciated with cause-specific mortality most likely representing two
different disease entities, the concern is that a systemic therapeutic
increase of apoE—of potential benefit for dementia—could possibly
generate harmful hypertriglyceridaemia peripherally due to apoE
stimulated very low-density lipoprotein triglyceride production in the
liver and apoE inhibited lipoprotein lipase mediated lipolysis as indi-
cated by mechanistic studies.42 Vice versa, a systemic therapeutic de-
crease of apoE—of potential benefit for ischaemic heart disease due
to decreased levels of atherogenic triglyceride-rich lipoproteins—
could possibly generate harmful effects in the brain, as supported by
experimental evidence in mice,69–72 and indirectly by large human
population studies.17,23,24,73 Whether plasma apoE could be a modifi-
able risk factor for dementia, rather than simply a risk marker, is a
crucial question to solve. This would however require that thera-
peutically modified high plasma apoE level also should be reflected in
a high brain apoE level. As brain and periphery are two separate com-
partments this can only be done by whole body APOE overexpres-
sion, which may result in potential detrimental hypertriglyceridaemic
effects in plasma.42,43 Alternatively, whole body overexpression of
ABCA1 which experimentally increases lipidation of apoE-containing
lipoproteins and decreases brain amyloid burden,74 may be a way to
increase apoE levels in the brain without potential detrimental hyper-
triglyceridaemic effects in plasma. Also, small molecule inducers of
ABCA1 and apoE that act through indirect activation of the LXR
pathway may be a future pharmacological possibility for dementia
without the known hepatotoxic side-effects caused by LXR ligands.75
Naturally, these speculations are purely theoretical and can only be
confirmed or rebutted in randomized clinical trials. Alternatively, spe-
cific therapeutics only targeting brain apoE or liver-derived apoE
could be considered.
A major strength of the study is the large prospective general popu-
lation design with no losses to follow-up: that is, every single individual
could be followed to end of follow-up, death, or emigration. Further,
due to the large sample size, we were able to perform analyses
adjusted for APOE genotype as well as analyses for APOE e33 carriers
alone. Finally, by performing APOE adjusted and stratified analyses we
Figure 5 Multifactorially adjusted hazard ratios for all-cause and cause-specific mortality for septiles of apolipoprotein E in individuals in the general
population. Cox regression models were multifactorially adjusted for age (time scale), sex, body mass index, smoking, hypertension, diabetes, lipid-
lowering therapy, alcohol consumption, physical inactivity, education, postmenopausal status, hormonal replacement therapy, LDL cholesterol, HDL
cholesterol, triglycerides (all panels), with further adjustment for APOE genotype (upper panels) and in analyses restricted to e33 carriers (bottom
panels). For cause-specific mortality, there are three parallel analyses: when Bonferroni-correction is applied (P= 0.05/3 = 0.02), results for the first
septile of apoE for dementia-associated mortality does not adhere to this significance level (P= 0.04) and likewise for the second septile for cardiovas-
cular mortality (P= 0.03). All other results are unaffected. 95% CI, 95% confidence interval; apoE, plasma apolipoprotein E level; APOE, APOE e2/e3/e4
genotype; e33, APOE wildtype carriers.
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..were able to differentiate the quantitative effects of apoE levels from
the genetically determined isoform specific qualitative effects.
One potential limitation concerns the availability and complete-
ness of the diagnostic information; however, the national Danish
Patient Registry includes all hospital visits, as well as out-patient visits.
Dementia diagnoses in the Danish registries have high diagnostic
validity.24,76 Further, myocardial infarction and cancer as a primary
diagnosis or underlying cause of death has been shown to have high
diagnostic validity.77,78 Unregistered contributing causes of death
would only lead to decreased power of our estimate and bias our
results towards the null hypothesis. Given the Danish registration
practice it is highly unlikely that an event of death would remain
Figure 6 Risk of cause-specific mortality for a 1 mg/dL change in observational and causal, genetically determined plasma apolipoprotein E level.
The hazard ratio for a 1 mg/dL change in observational plasma apoE was calculated using Cox regression with adjustment for age (time scale), body
mass index, smoking, hypertension, diabetes, lipid-lowering therapy, alcohol consumption, physical inactivity, education, postmenopausal status, hor-
monal replacement therapy, LDL cholesterol, HDL cholesterol, plasma triglycerides, and APOE genotype, whereas the corresponding risk ratios for
the genetic change in plasma apoE for the weighted allele score was derived from univariable and multivariable instrumental variable analyses, includ-
ing LDL cholesterol and triglycerides in multivariable analyses. A total of 74 560 individuals are included in these analyses. apoE, apolipoprotein E; CI,
confidence interval; F, strength of the genetic instrument (>10 indicates sufficient statistical strength); P-value, significance of hazard ratios or risk
ratios; R2, percent contribution of genetic instrument to the variation in plasma apoE.
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unregistered. Another potential limitation is that blood samples were
not drawn in the fasting state, which could add to random measure-
ment error. However, plasma levels of apoE vary only slightly be-
tween the fasting and non-fasting state.60,79 Finally, another limitation
could be that the generalizability of our study results is limited by the
fact that we studied only white individuals. Our results may therefore
not necessarily apply to other ethnicities, although we are not aware
of data to suggest that our results should not be applicable to all
humans.
Conclusion
In conclusion, we found that high plasma levels of apoE were associ-
ated with all-cause, cardiovascular, and cancer mortality, however of
Take home ﬁgure Epidemiological and causal relationship of plasma apolipoprotein E levels and cardiovascular and dementia-associated mor-
tality in the Copenhagen General Population Study and the Copenhagen City Heart Study. apoE, apolipoprotein E; CI, confidence interval.
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.
a non-causal nature, while low apoE levels were causally associated
with dementia-associated mortality.
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Supplementary material is available at European Heart Journal online.
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